Pfizer - Articles and news items

Private and public partners unite to combat 10 neglected tropical diseases by 2020

Industry news, News / 30 January 2012 /

Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.

(more…)

Pfizer announces FDA acceptance of New Drug Application for Bosutinib

Industry news, News / 27 January 2012 / Pfizer

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). This submission was based on efficacy and safety data from Study 200, a single-arm study of bosutinib in over 500 patients with previously treated Ph+ CML, including patients resistant or intolerant to imatinib as well as patients who were previously treated with dasatinib or nilotinib. Currently, there are no approved therapies available for CML patients after second-line treatment with dasatinib or nilotinib.

(more…)

U.S. Food and Drug Administration approves Pfizer’s INLYTA® (axitinib)

Industry news, News / 27 January 2012 / Pfizer

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The approval is based on data from the Phase 3 AXIS trial, which demonstrated that INLYTA significantly extended progression free survival (PFS) [HR=0.67, 0.54-0.81, P<0.0001] with a median PFS of 6.7 months (95% CI: 6.3, 8.6) compared with 4.7 months (95% CI: 4.6, 5.6) for those treated with sorafenib, a current standard of care for this patient population, representing a 43 percent improvement in median PFS compared to sorafenib.

(more…)

Medivation and Pfizer announce results from Phase 3 Concert trial of dimebon in Alzheimer’s disease

Industry news, News / 17 January 2012 / Pfizer

Medivation, Inc. (NASDAQ: MDVN) and Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 trial that evaluated dimebon (latrepirdine) when added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer’s disease. Dimebon did not achieve statistically significant results for either of the two co-primary endpoints, the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog), which measures cognitive ability, or the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL), which measures self care and daily function.

(more…)

SFJ Pharma Ltd. II announces agreement with Pfizer to develop Axitinib

Industry news, News / 9 January 2012 / Citigate Dewe Rogerson

SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, “SFJ”) announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer’s investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

(more…)

Pfizer receives FDA approval to extend use of Prevnar 13®

Industry news, News / 30 December 2011 / Pfizer

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae) serotypes contained in the vaccine.

(more…)

Pfizer reports positive results from Phase 3 trial Of Lyrica (pregabaline)

Industry news / 19 December 2011 / Pfizer

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. (more…)

Drug discovery leaders roundtable

Latest issue / 13 December 2011 / Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline and Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer and William Strohl, Vice President of Biologics Research, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development and Eckhard von Keutz, Senior Vice President, Head Global Early Development, Bayer HealthCare

Andrew A. Parsons, Vice President Preclinical Drug Development, GlaxoSmithKline

Dr. Parsons has led the Preclinical Development function in the CEDD since its creation. He was previously the Head of Preclinical Development for the Neurology and Gastrointestinal (NGI) Center of Excellence for Drug Discovery (CEDD) and a member of the Executive Leadership Team. Dr. Parsons joined SmithKline Beecham in 1991 as a lead biologist on the Migraine Program and played a key role in the identification and development of Frovatriptan and Tonabersat. He has worked in a number of therapy areas within drug discovery and has led teams that progressed numerous compounds in development. He was also previously the Chairman of the Imitrex (Sumatriptan) International Scientific Advisory Board. Dr. Parsons graduated with a BSc, MSc and PhD in Pharmacology, University of Manchester and is a qualified NLP practitioner and Cognitive Therapist. He worked as a post-doctoral researcher at the Institute of Physiology, University of Munich, Germany. He has authored more than 90 peer-reviewed publications.

Steve Street, Vice President, Head of Research Centres of Emphasis, Head of WRD Continuous Improvement, Pfizer

Steve Street joined Pfizer in 1985 and held a variety of roles within the Chemistry Department in Sandwich UK, before being appointed Head of Chemistry for Sandwich Discovery in 2001. Three years later, at the start of 2004, Steve moved to establish and lead the Chemistry discipline across Worldwide Discovery. Steve held this role through to early 2007 when he was delighted to be asked to take on a new role as Head of the Research Centers of Emphasis, covering a range of activities supporting Worldwide Research including External Research, BioImaging, Computational Sciences and High Throughput Screening. In April 2008, Steve was asked to become Head of Continuous Improvement across all of Pfizer Worldwide Research and Development where his focus was uniquely on improving project and portfolio survival and cycle times. (more…)

Pfizer elects CEO Ian Read as Chairman of the Board

Industry news, News / 12 December 2011 / Pfizer

Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately. Mr. Read succeeds George Lorch as Chairman of the Board. The independent members of the board named Mr. Lorch as Lead Independent Director.

(more…)

Pfizer completes acquisition of Excaliard

Industry news, News / 2 December 2011 / Pfizer

Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring.

(more…)

Pfizer completes acquisition of Ferrosan Consumer Health’s Business

Industry news, News / 1 December 2011 / Pfizer

Pfizer Inc. (NYSE:PFE) today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

(more…)

FDA accepts ELIQUIS® (apixaban) New Drug Application for review

Industry news, News / 29 November 2011 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned a priority-review designation. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is March 28, 2012.

(more…)